The goal seemed insurmountable: use the immune system to fight cancer. We achieved it. Learn more about Dana-Farber's immunotherapy breakthroughs.
Is this the best time in a long time to be buying biotech stocks now that their lagging performance has made them relatively undervalued to other sectors? Todd Hagopian is buying because he believes the biotech industry is ripe for acquisitions as large, cash-flow rich drug companies look for promising new products. This is the 2nd in a three-part series focusing on potential mergers and acquisitions in the biotech sector.
Portola Pharmaceuticals, Inc.NasdaqGS
After hours: 24.320.12 (0.50%) as of 5:43 PM EDT
|Bid||23.05 x 300|
|Ask||24.50 x 100|
|52wk Range||18.20 - 57.96|
|Day's Range||23.61 - 24.40|
|Avg Vol (3m)||631,998|
As of 4:00 PM EDT. Market closed.